Cargando…
Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review
INTRODUCTION: Despite antiretroviral (ARV) therapy reducing renal disease in human immunodeficiency virus overall, there is concern that certain ARVs, particularly tenofovir disoproxil fumarate (TDF) with or without a boosted protease inhibitor (PI), may reduce renal function over time. It is not kn...
Autores principales: | Bagnis, Corinne Isnard, Stellbrink, Hans-Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363218/ https://www.ncbi.nlm.nih.gov/pubmed/25567681 http://dx.doi.org/10.1007/s40121-014-0056-4 |
Ejemplares similares
-
Hepatitis C Therapy in Renal Patients: Who, How, When?
por: Isnard Bagnis, Corinne, et al.
Publicado: (2016) -
Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009) -
Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV
por: Heron, Jack Edward, et al.
Publicado: (2020) -
Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons
por: Stellbrink, Hans-Jürgen
Publicado: (2014) -
Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)